Suven grants exclusive license for Malathion lotion to Taro Pharmaceuticals in North America

The Hyderabad-based Suven Life Sciences Ltd has granted an exclusive license and right to distribute and market its Malathion lotion USP 0.5% w/v in USA, Canada and Mexico to Taro Pharmaceuticals North America, Inc, a subsidiary of Taro Pharmaceutical Industries Ltd.
 
Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. In consideration for the exclusive license and right to distribute and market Malathion Lotion 0.5%w/v USP in North America, Taro will pay Suven a royalty and the arrangement is effective until April 2028 unless otherwise terminated.